| CTC\_group | control | exercise |
| --- | --- | --- |
| Cardiac disorders | 1 |  |
| Gastrointestinal disorders | 1 | 10 |
| General disorders and administration site conditions | 2 | 29 |
| Infections and infestations | 2 | 4 |
| Metabolism and nutrition disorders | 1 |  |
| Musculoskeletal and connective tissue disorders | 2 | 35 |
| Nervous system disorders | 1 | 11 |
| Renal and urinary disorders | 1 |  |
| Skin and subcutaneous tissue disorders | 1 | 1 |
| Ear and labyrinth disorders |  | 1 |
| Eye disorders |  | 1 |
| Fever |  | 1 |
| Psychiatric disorders |  | 4 |
| Respiratory, thoracic and mediastinal disorders |  | 7 |
| Social circumstances |  | 1 |
| Vascular disorders |  | 1 |
| Supplemental Figure - Total count of adverse events by randomization divided into CTC categories    This method does not take into account that the exercisers were asked for symptoms before, during and after exercise, as well as AEs being noted when exercisers cancelled sessions due to illness, there is a significant bias to having more AEs in this case. | | |